HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

419.757

-17.440-3.99%

Number of Gainers:5

Number of Losers:27

Number of Flat:2

PE:- -

High:441.043

Open:436.588

Low:416.263

Close:437.197

Loading ...

BUZZ-HK-listed Alphamab Oncology jumps on expectation of first annual profit

BRIEF-Alphamab Oncology Sees Profit Of Not Less Than RMB150.0 Million For Year

Alphamab Oncology - Expected Result Due to Three License Collaborations and Sales Revenue in FY

THOMSON REUTERS

Alphamab Oncology Sees Profit of Not Less Than RMB150.0 Mln for Year

THOMSON REUTERS

CStone Pharmaceuticals Carries Out First Dosing in Multi-Cancer Drug Trial

MT Newswires Live

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of Cs2009, a Pd-1/Vegf/Ctla-4 Trispecific Antibody

THOMSON REUTERS

Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week

Simply Wall St.

CARsgen's Claudin18.2 CAR-T Therapy Satri-Cel Granted Breakthrough Therapy Designation by the Nmpa

THOMSON REUTERS

Immunotech Biopharm - Center for Drug Evaluation Agreed Group May Submit Application for Conditional Approval for Core Product Candidate, Eal

THOMSON REUTERS

Zai Lab Ltd : Leerink Partners Raises Target Price to $74 From $72

THOMSON REUTERS

Zai Lab Ltd Outlook FY 2025 Total Revenue $560 Mln to $590 Mln

THOMSON REUTERS

Zai Lab Ltd - Q4 Total Revenues $109.1 Million

THOMSON REUTERS

CARsgen Therapeutics to Trim Stake in Biotech Arm After Third-Party Investment

MT Newswires Live

Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

THOMSON REUTERS

When Will Ocumension Therapeutics (HKG:1477) Turn A Profit?

Simply Wall St.

BRIEF-Carsgen Therapeutics Says Introduction Of Zhuhai Sb Xinchuang In China

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK1574/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":419.75656,"timestamp":1741594084391,"preClose":437.19687,"halted":0,"volume":125062844,"delay":0,"changeRate":-0.039891,"change":-17.440308,"pbRate":3.43319,"amount":2228559126,"amplitude":0.056681,"prevYearClose":331.1933,"fiveDayClose":410.09,"twentyDayClose":340.813,"turnoverRate":0.004845,"marketCap":234571806688,"floatMarketCap":221135631584,"peRate":-17.305245},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":441.04327,"amplitude":0.056681,"preClose":437.19687,"low":416.2626,"pbRate":"3.43319","latestPrice":419.75656,"volume":125062844,"delay":0,"open":436.5877,"prevYearClose":331.1933,"prevWeekClose":437.197,"prevMonthClose":411.011,"prevQuarterClose":331.193,"fiveDayClose":410.09,"twentyDayClose":340.813,"sixtyDayClose":341.701,"secType":"PLATE","market":"HK","turnoverRate":0.004845,"peRate":-17.305245,"marketCap":234571806688,"floatMarketCap":221135631584,"timestamp":1741594084391,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":5,"down":27,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517956763","title":"BUZZ-HK-listed Alphamab Oncology jumps on expectation of first annual profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2517956763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517956763?lang=en_us&edition=fundamental","pubTime":"2025-03-05 11:58","pubTimestamp":1741147114,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed Alphamab Oncology jumps on expectation of first annual profit  ** Shares of Alphamab Oncology 9966.HK jump as much as 15.8% to HK$6.07, set for biggest one-day pct gain since February 27** Stock top pct gainer on healthcare index .HSCIH, which is up 1.1%** The oncology drugs developer expects to record a net profit of 150 mln yuan  for 2024 as compared to a loss of 210.6 mln yuan in 2023; this is the first time the company expects to achieve an annual profit** The Hang Seng Commerce & Industry Index .HSNC jumps 1.9%, Hang Seng Index .HSI rises 1.6%** Stock up 73.4% YTD    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL2N3PO06W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2516672802","title":"BRIEF-Alphamab Oncology Sees Profit Of Not Less Than RMB150.0 Million For Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2516672802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516672802?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:29","pubTimestamp":1741098563,"startTime":"0","endTime":"0","summary":"BRIEF-Alphamab Oncology Sees Profit Of Not Less Than RMB150.0 Million For YearMarch 4  - Alphamab Oncology 9966.HK:SEES PROFIT OF NOT LESS THAN RMB150.0 MILLION FOR YEAREXPECTED RESULT DUE TO THREE LICENSE COLLABORATIONS AND SALES REVENUE IN FYFurther company coverage: 9966.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2516620764","title":"Alphamab Oncology - Expected Result Due to Three License Collaborations and Sales Revenue in FY","url":"https://stock-news.laohu8.com/highlight/detail?id=2516620764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516620764?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:06","pubTimestamp":1741089999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0FF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2516207616","title":"Alphamab Oncology Sees  Profit of Not Less Than RMB150.0 Mln for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2516207616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516207616?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:06","pubTimestamp":1741089999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2516144536","title":"CStone Pharmaceuticals Carries Out First Dosing in Multi-Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516144536","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516144536?lang=en_us&edition=fundamental","pubTime":"2025-03-04 13:43","pubTimestamp":1741067010,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  said the first patient was successfully dosed in the global multicenter Phase I clinical trial of its independently developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, without infusion reactions or other adverse events, according to a Tuesday filing with the Hong Kong Stock Exchange.CS2009 is a trispecific antibody targeting PD-1, VEGFA, and CTLA-4 to boost the immune response against tumors. It is designed to reinvigorate exhausted immune cells while neutralizing VEGF, making it a potential breakthrough for various cancers, including lung, liver, and ovarian cancer, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2516608698","title":"CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of Cs2009, a Pd-1/Vegf/Ctla-4 Trispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516608698?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:10","pubTimestamp":1741047002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA2RYCFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"2516708635","title":"Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2516708635","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516708635?lang=en_us&edition=fundamental","pubTime":"2025-03-03 12:06","pubTimestamp":1740974772,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Everest Medicines by retail investors implies that the general public has more...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limiteds-hkg1952-biggest-owners-are-retail","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","MDCO","BK1583","01952","BK1574"],"gpt_icon":0},{"id":"2516930525","title":"CARsgen's Claudin18.2 CAR-T Therapy Satri-Cel Granted Breakthrough Therapy Designation by the Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2516930525","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516930525?lang=en_us&edition=fundamental","pubTime":"2025-03-03 08:15","pubTimestamp":1740960905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUANP7GF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1585","BK1574","BK1587","02171"],"gpt_icon":0},{"id":"2514312425","title":"Immunotech Biopharm - Center for Drug Evaluation Agreed Group May Submit Application for Conditional Approval for Core Product Candidate, Eal","url":"https://stock-news.laohu8.com/highlight/detail?id=2514312425","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514312425?lang=en_us&edition=fundamental","pubTime":"2025-02-28 16:35","pubTimestamp":1740731756,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ0MO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2514382028","title":"Zai Lab Ltd : Leerink Partners Raises Target Price to $74 From $72","url":"https://stock-news.laohu8.com/highlight/detail?id=2514382028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514382028?lang=en_us&edition=fundamental","pubTime":"2025-02-28 00:28","pubTimestamp":1740673738,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI25V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1588","BK4531","BK1161","BK4588","BK4139","BK4526","BK4548","ZLAB","BK1574","BK4585","LU2488822045.USD","09688"],"gpt_icon":0},{"id":"2514877985","title":"Zai Lab Ltd Outlook  FY 2025 Total Revenue $560 Mln to $590 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514877985","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514877985?lang=en_us&edition=fundamental","pubTime":"2025-02-27 19:07","pubTimestamp":1740654467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI15X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09688","BK1161","BK1588","BK1574","LU2488822045.USD"],"gpt_icon":0},{"id":"2514487798","title":"Zai Lab Ltd - Q4 Total Revenues $109.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514487798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514487798?lang=en_us&edition=fundamental","pubTime":"2025-02-27 19:07","pubTimestamp":1740654467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI15X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09688","BK1588","BK1574","LU2488822045.USD"],"gpt_icon":0},{"id":"2514987977","title":"CARsgen Therapeutics to Trim Stake in Biotech Arm After Third-Party Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2514987977","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514987977?lang=en_us&edition=fundamental","pubTime":"2025-02-27 18:13","pubTimestamp":1740651198,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics'  equity interest in subsidiary, UCARsgen Biotech, will decline to 92% from 100% after an investment fund subscribes for its additional registered capital for 80 million yuan, a Wednesday filing with the Hong Kong bourse said.The investment fund is being managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management, according to the biopharmaceutical company.Under the contract, UCARsgen Biotech has secured the exclusive rights for the R&D, manufacture, and commercialization of two allogeneic CAR-T products in mainland China.UCARsgen Biotech is a new drug discovery biotechnology company focused on allogeneic CAR-T cell therapies for the treatment of hematologic malignancies.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0348723411.USD","BK1574","BK4588","LENZ","BK4585","IE00BMPRXR70.SGD","BK1585","BK4141","BK4139","BK4543","BK4609","IE00BMPRXQ63.HKD","BK1161","IE00BMPRXN33.USD","BK1587","02171"],"gpt_icon":1},{"id":"2514270658","title":"Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for \"IO 2.0 + ADC\" Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514270658","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514270658?lang=en_us&edition=fundamental","pubTime":"2025-02-27 16:58","pubTimestamp":1740646720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nTUA82CJGQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0348783233.USD","LU1720050803.USD","IE00BPRC5H50.USD","BK1161","IE00B543WZ88.USD","IE00B5MMRT66.SGD","09926","BK1574","LU0348784397.USD","LU1794554557.SGD","LU2488822045.USD","LU0417516571.SGD"],"gpt_icon":0},{"id":"2514812683","title":"When Will Ocumension Therapeutics (HKG:1477) Turn A Profit?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514812683","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514812683?lang=en_us&edition=fundamental","pubTime":"2025-02-27 07:34","pubTimestamp":1740612844,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Ocumension Therapeutics...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1477/ocumension-therapeutics-shares/news/when-will-ocumension-therapeutics-hkg1477-turn-a-profit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK4139","LENZ","01477","BK1191"],"gpt_icon":0},{"id":"2514854243","title":"BRIEF-Carsgen Therapeutics Says Introduction Of Zhuhai Sb Xinchuang In China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514854243","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514854243?lang=en_us&edition=fundamental","pubTime":"2025-02-26 23:41","pubTimestamp":1740584468,"startTime":"0","endTime":"0","summary":"BRIEF-Carsgen Therapeutics Says Introduction Of Zhuhai Sb Xinchuang In ChinaFeb 26 (Reuters) - CARsgen Therapeutics 2171.HK:INTRODUCTION OF ZHUHAI SB XINCHUANG TO ACCELERATE ALLOGENEIC CAR-T CELL PROD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1585","BK1574","02171","BK1587"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":3,"totalSize":62}]}}